摘要
目的观察非ST段抬高急性冠脉综合征(NSTEACS)的老年患者在常规治疗基础上加用替罗非班治疗的近期临床效果。方法将符合NSTEACS高危患者200例根据是否应用替罗非班随机分为治疗组100例(替罗非班加常规治疗)和对照组100例(常规治疗)。观察两组患者治疗36 h及30 d后的主要不良心血管事件(MACE)及不良反应的发生情况。结果治疗后36 h及30 d后,治疗组不良心血管事件的发生率明显低于对照组,差异具有统计学意义(P<0.05)。两组均无严重的出血并发症及血小板减少,皮肤、黏膜出血发生率差异无统计学意义(P>0.05)。结论老年NSTEACS患者联用盐酸替罗非班治疗可减少不良心血管事件的发生率,是一种安全有效的治疗方式。
Objective To observe the clinical effect of Tirofiban on the patients with non ST elevation acute coronary syndrome （NSTEACS）. Methods A total of 200 NSTEACS patients were divided into two groups at random, i.e. trial group （n = 100） which received Tirofiban plus conventional treatment and control group （n = 100） which received conventional therapy without Tiro- fiban. The occurrence of major adverse cardiovascular event （MACE） and adverse reaction was observed after 36 hours＇ and 30 days＇ treatment. Results The MACE rate of the trial group was statistically lower than that of the control group after 36 hours＇ and 30 days＇ treatment （P 〈 0.05 ）. There were no complications such as severe bleeding and thrombocytopenia in both the two groups, and the mueosal bleeding incidences of the two groups were of no difference （ P 〉 0.05 ）. Conclusion In addition to conventional therapy, Tirofiban hydrochloride can reduce the incidence of MACE, and is a safe and effective treatment.
出处
《临床军医杂志》
CAS
2013年第4期338-339,346,共3页
Clinical Journal of Medical Officers
作者简介
梁莉（1980-），女，湖南常德人，主治医师，目前主要从事心血管内科工作
